Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Unity Biotechnology Inc (NQ: UBX )

1.480 -0.010 (-0.70%)
Streaming Delayed Price Updated: 3:11 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 77,887
Open 1.500
Bid (Size) 1.470 (5)
Ask (Size) 1.480 (2)
Prev. Close 1.490
Today's Range 1.460 - 1.510
52wk Range 1.470 - 3.820
Shares Outstanding 14,601,258
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
From Unity Biotechnology, Inc.
Via GlobeNewswire
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga

Performance

YTD
-22.94%
-22.94%
1 Month
-6.36%
-6.36%
3 Month
-15.46%
-15.46%
6 Month
-18.71%
-18.71%
1 Year
-32.44%
-32.44%

More News

Read More
UBX Stock Earnings: Unity Biotechnology Beats EPS for Q4 2023
Via InvestorPlace
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
Analyst Ratings for Unity Biotechnology
Via Benzinga
The Latest Analyst Ratings for Unity Biotechnology
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
From Unity Biotechnology, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Where Unity Biotechnology Stands With Analysts
Via Benzinga
Recap: Unity Biotechnology Q1 Earnings
Via Benzinga
Where Unity Biotechnology Stands With Analysts
Via Benzinga
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME
From Unity Biotechnology, Inc.
Via GlobeNewswire
Unity Biotechnology Upgraded - Analyst Highlights Cash Strength & Execution
Via Benzinga
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
From Unity Biotechnology, Inc.
Via GlobeNewswire
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks
Via InvestorPlace
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 26, 2023
Via Benzinga
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
From Unity Biotechnology, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023
Via Benzinga
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
Unity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's Eylea
Via Benzinga
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
From Unity Biotechnology, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.